Globus Medical (NYSE:GMED) Trading Down 6.5% – What’s Next?

Shares of Globus Medical, Inc. (NYSE:GMED) dropped 6.5% during mid-day trading on Tuesday . The company traded as low as $76.88 and last traded at $78.46. Approximately 192,185 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,434,343 shares. The stock had previously closed at $83.94.

Analysts Set New Price Targets

GMED has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company dropped their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Piper Sandler cut their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical Stock Down 3.8%

The company has a market capitalization of $10.32 billion, a P/E ratio of 17.67, a P/E/G ratio of 1.63 and a beta of 0.95. The company’s 50-day simple moving average is $82.66 and its 200 day simple moving average is $87.22.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the business posted $0.68 EPS. Globus Medical’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is owned by insiders.

Institutional Trading of Globus Medical

Several large investors have recently made changes to their positions in GMED. Advisory Services Network LLC bought a new position in shares of Globus Medical in the 3rd quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. grew its holdings in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the last quarter. Parallel Advisors LLC grew its holdings in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC raised its position in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.